LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced it will host its first R&D Day from 10:00 a.m. to 1:30 p.m. EST on December 17th in New York City. Members of the Inotek management team and distinguished guest speakers will provide an overview of glaucoma and other optic nerve neuropathies, and the Company’s lead product candidate, trabodenoson, a first-in-class selective adenosine mimetic currently in Phase 3 development.
